References
- Irwin RS, Richardson ND. Side effects with inhaled corticosteroids. Chest130, 41–53 (2006).
- Gold DR, Fuhlbrigge AL. Inhaled corticosteroids for young children with wheezing. N. Engl. J. Med.354, 2058–2060 (2006).
- Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy61(7), 843–848 (2006).
- Akdis CA, Barlan IB, Bahceciler N, Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy61(Suppl. 81), 11–14 (2006).
- Ciprandi G, Marseglia GL, Tosca MA. Allergen-specific immunotherapy: an update on immunological mechanisms of action. Monaldi Arch. Chest Dis.65(1), 34–37 (2006).
- Yang X. Does allergen immunotherapy alter the natural course of allergic disorders? Drugs61(3), 365–374 (2001).
- Dursun AB, Sin BA, Oner F, Misirligil Z. The safety of allergen immunotherapy (IT) in Turkey. J. Investig. Allergol. Clin. Immunol.16(2), 123–128 (2006).
- Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. J. Allergy Clin. Immunol.102, 558–562 (1998).
- Reyes Moreno A, Castrejon Vazquez MI, Miranda Feria AJ. Failure of allergen-based immunotherapy in adults with allergic asthma. Rev. Alerg. Mex.50(1), 8–12 (2003).
- Rossi RE, Monasterolo G, Coco G, Operti D. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int. Arch. Allergy Immunol.138(2), 105–110 (2005).
- Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.117(2), 319–325 (2006).
- Ferreira F, Briza P, Infuhr D et al. Modified recombinant allergens for safer immunotherapy. Inflamm. Allergy Drug Targets5(1), 5–14 (2006).
- Colas C, Monzon S, Venturini M, Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J. Allergy Clin. Immunol.117(4), 810–816 (2006).
- Korematsu S, Tanaka Y, Hosoi S et al. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J. Immunol.165(5), 2895–2902 (2000).